Radiopharmaceutical developer Navidea Biopharmaceuticals is highlighting results published in the Annals of Surgical Oncology from a phase III clinical trial of its Lymphoseek radiopharmaceutical agent.
The trial assessed the performance of Lymphoseek-guided sentinel node biopsy against the standard of care, nodal pathology, in planned elective neck dissection procedures. It was conducted by Dr. Amit Agrawal, from Ohio State University Wexner Medical Center, and colleagues (Ann Surg Onc, February 11, 2015).
Lymphoseek accurately identified sentinel lymph nodes in subjects with node-negative squamous cell carcinoma of the oral cavity, compared with the removal of all lymph nodes during multiple-level nodal dissection surgery of the head and neck, according to the firm.
